普通精神病学纪要2013-09-05 2:57 AM

Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside A Randomized, Double-blind, Placebo-Controlled Trial

Abstract Importance: The treatment of schizophrenia remains a challenge, and the currently available antipsychotic drugs are slow acting and produce a number of adverse effects. Objective: To examine the effectiveness and safety of a single intravenous administration of sodium nitroprusside (0.5 μg/kg/min for 4 hours) on the positive, negative, anxiety, and depressive symptoms in patients with schizophrenia. Design: Single-center, randomized, double-blind, placebo-controlled trial performed from March 9, 2007, to March 12, 2009. Setting: University teaching hospital in São Paulo, Brazil. Participants: Twenty inpatients aged 19 to 40 years with a diagnosis of schizophrenia who were in the first 5 years of the disease who are taking antipsychotics. Intervention: Sodium nitroprusside administration. Main Outcome Measures: The 18-item Brief Psychiatric Rating Scale and the negative subscale of the Positive and Negative Syndrome Scale. Results: After the infusion of sodium nitroprusside, a rapid (within 4 hours) improvement of symptoms was observed. The placebo and experimental groups had significant differences in the 18-item Brief Psychiatric Rating Scale total score and subscale scores, which persisted for 4 weeks after infusion. Conclusions: The results clearly show a therapeutic effect of sodium nitroprusside. If this drug is approved for routine clinical use in patients with schizophrenia, this discovery will be an important advance in the pharmacologic treatment of this devastating disorder. Trial Registration: clinicaltrials.gov Identifier: NCT01548612

KEYWORDS

SHARE & LIKE

COMMENTS

ABOUT THE AUTHOR

普通精神病学纪要

0 Following 1 Fans 0 Projects 84 Articles

SIMILAR ARTICLES

Context Schizophrenic symptoms are linked to a dysfunction of dopamine neurotransmission and the brain reward system. However, it remains unclear whet

Read More

Context Schizophrenic symptoms are linked to a dysfunction of dopamine neurotransmission and the brain reward system. However, it remains unclear whet

Read More

Context Schizophrenia is a common, highly heritable, neurodevelopmental mental illness, characterized by genetic heterogeneity. Objective To ident

Read More

Context Schizophrenia is a common, highly heritable, neurodevelopmental mental illness, characterized by genetic heterogeneity. Objective To ident

Read More

Context Schizophrenia remains a highly disabling disorder, but the specific determinants and pathways that lead to functional impairment are not well

Read More

Context Schizophrenia remains a highly disabling disorder, but the specific determinants and pathways that lead to functional impairment are not well

Read More

Context Iatrogenic obesity caused by atypical antipsychotics increases the rate of death from all causes. Olanzapine is a commonly prescribed atypical

Read More

Context Iatrogenic obesity caused by atypical antipsychotics increases the rate of death from all causes. Olanzapine is a commonly prescribed atypical

Read More

Context Brain-derived neurotrophic factor (BDNF) is suspected of being a causative factor in psychiatric disorders based on case reports or studies in

Read More

Context Brain-derived neurotrophic factor (BDNF) is suspected of being a causative factor in psychiatric disorders based on case reports or studies in

Read More